ArticlePloS one2026
Machine learning-based analysis of drug resistance mutations in Mycobacterium tuberculosis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis is a deadly airborne disease caused by Mycobacterium tuberculosis. Drug-resistant tuberculosis presents significant challenges for treatment and control of the disease. Resistant strains of Mycobacterium tuberculosis arise from specific mutations in the bacterium. Identification and characterization of resistance-associated mutations are crucial for effective treatment strategies because the first- and second-line drugs for the disease target distinct genes in the bacterium and serve different purposes. Our study developed a machine learning prediction model to analyze mutations across multiple drug-resistance types. The proposed framework predicts drug-resistance mutations across four drug-resistance types, including Rifampicin Resistance, Isoniazid Resistance, Multidrug Resistance, and Pre-extensively Drug-Resistant tuberculosis. The NIAID-NIH TB portal is a publicly available dataset of tuberculosis patients, including drug-resistance information. Our study analyzed 3,065 cases of drug-resistant TB. Eight supervised ML algorithms were implemented for the study. A Random Forest classifier with 10-fold cross-validation shows higher predictive performance than the other seven algorithms considered for further analysis. Significant drug resistance mutations were identified using SHapley Additive exPlanations feature importance. The World Health Organisation mutation catalogues, considered the gold standard for drug-resistant mutations, were used to evaluate prediction results. Mutations not reported in the WHO catalogues were identified during the post-prediction comparative analysis stage, as they may represent potential resistance-conferring markers warranting further investigation, including structural and functional validation or experimental validation. The mutations are rpoB-I480T, rpoC-G332R, L527V, gyrA-D94V, KatG-G99E, A106V, W191R, W328C, T380I, and M420T. The study further checks the stability and pathogenicity of the mutations using computational tools, including I-Mutant 2.0 and PredictSNP. The findings added more clarity and further evidence for the significance of the mutation, based on its contribution to drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.